Valiant Laboratories Ltd
As of 20 Nov 2026, Valiant Laboratories is in Stage 2, the uptrend phase, now in week 12 (since 25 Aug 2026). It closed at ₹94.91, 32.6% below its 52-week high and above its 200-day average, which is rising. In Health Care, 34.7% of stocks are in Stage 2.
Valiant Laboratories Limited operates as an active pharmaceutical ingredient/bulk drug manufacturing company in India and internationally. More about the company
Pro read
ProVALIANTLAB is about 3 months into its Stage 2 advance, 21% below its 50-day average and 33% under its 52-week high. A pause below the 50-day inside an uptrend is the weakest spot of the move until it closes back above the line.
Its relative strength is 79 of 99, above the middle among NSE stocks over the past year. Pharmaceuticals ranks 7 of 106 industries by the strength of its stocks, among the leaders.
Stocks with a similar setup at this point in their move ran 1.4 points behind the average stock over the next 30 sessions on average, after costs, and their typical best close within 60 sessions was 12% above entry.
The trend read holds while it stays in Stage 2. A close below ₹120, its 50-day average, would put it at rest; ₹113, 20% under its 52-week high of ₹141, is where a trailing stop would sit.
Setup-score rank among Stage 2 peers: #42 of 50 in Pharmaceuticals · #51 of 61 in Health Care
Is VALIANTLAB early, or has it already run? Pro answers that for every NSE stock, after every close.
VALIANTLAB among Pharmaceuticals46th of 118 by relative strength
All 118 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | BLISSGVS | Stage 2 · wk 49 | 99 | +4.6% |
| 2 | KPL | Stage 2 · wk 44 | 99 | +20.5% |
| 3 | FREDUN | Stage 2 · wk 33 | 98 | +24.0% |
| 4 | VENUSREM | Stage 3 · wk 10 | 98 | −1.5% |
| 5 | RUBICON | Stage 3 · wk 4 | 98 | +18.7% |
| 6 | SAKAR | Stage 2 · wk 55 | 98 | +13.1% |
| 7 | BAFNAPH | Stage 2 · wk 23 | 98 | +1.9% |
| 8 | INDSWFTLAB | Stage 2 · wk 23 | 98 | −7.4% |
| …46 | VALIANTLAB | Stage 2 · wk 12 | 79 | −29.0% |
Valiant Laboratories: quick answers
What stage is Valiant Laboratories in?
As of 20 Nov 2026, Valiant Laboratories (VALIANTLAB) is in Stage 2, the uptrend phase. It entered Stage 2 on 25 Aug 2026 and is in week 12. What the four stages mean
Is Valiant Laboratories in an uptrend?
Yes. Valiant Laboratories is in a Stage 2 uptrend. It trades 15.9% above its 200-day average, which is rising.
How far is Valiant Laboratories from its 52-week high?
Valiant Laboratories closed at ₹94.91 on 20 Nov 2026, 32.6% below its 52-week high of ₹141. Its 52-week low is ₹50.93.
How has Valiant Laboratories performed over the past year?
As of 20 Nov 2026, Valiant Laboratories is up 19.1% over the past year and up 35.6% so far in 2026.
Which sector and industry is Valiant Laboratories in?
Valiant Laboratories is in the Pharmaceuticals industry, part of the Health Care sector. 61 stocks in Health Care are in Stage 2, 34.7% of the sector. See the Stage 2 stocks in Pharmaceuticals
About this companyHealth Care· Pharmaceuticals
Valiant Laboratories Limited operates as an active pharmaceutical ingredient/bulk drug manufacturing company in India and internationally. The company manufactures paracetamol in various grades, such as Indian/British/European/the United States pharmacopoeias for the treatment of headaches, muscle aches, arthritis, back aches, toothaches, cold, and fever. It also offers specialty chemicals. The company was formerly known as Bharat Chemicals and changed its name to Valiant Laboratories Limited in August 2021. The company was founded in 1980 and is based in Mumbai, India. Valiant Laboratories Limited is a subsidiary of Dhanvallabh Ventures LLP.
Visit company website →All analytics based on EOD data. Data as of 2026-11-20. Past data patterns are not indicative of future results. This page is a data analytics tool only.